The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
Haematology CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukaemia and lymphoma February 7, 2020 According to results from a Phase I/IIa trial at The University of Texas MD Anderson…